FDA ······························································································ 64
ICES-003 ······················································································ 64
VCCI ····························································································· 64
中国Class A声明 ··················································································· 65
Brazil Compliance ················································································ 65
економічна комісія ·············································································· 65
Korea Compliance ················································································ 66
ii